SLC5A2 and Stroke: Currently, no research on the risk of AF development with any of the SGLT-2 inhibitors has been published, but a sub-analysis of the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) acknowledged a slightly increased incidence of stroke in the empagliflozin treatment group, even though not reaching statistical significance [61].